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Background: Increasing evidence suggest that ubiquitin-proteasome system (UPS) plays a key role in tumorigenesis.
HERC4 is a recently identified ubiqutin ligase. However, the expression status and biological functions of HERC4 in
cancers are not clearly.
Methods: We evaluated the HERC4 expression in breast cancer cell lines and breast tumor tissues by
quantitative real-time PCR and western blot analysis. To investigate the clinicopathological significance of
HERC4, immunohistochemistry analysis for HERC4 was performed on a tissue microarray including 13 benign
fibroadenoma, 15 intraductal carcinoma, 120 histologically confirmed invasive ductal carcinoma. Receiver operating
characteristic (ROC) analysis was applied to determine the optimal cut-off score for positive expression of HERC4, when
HERC4 positive expression percentage was above 60%, tumor was defined as “positive”.
Results: HERC4 was up-regulated in breast cancer cell lines and breast tumor tissues compared to non-tumorigenic cell
line and adjacent normal breast tissues. According to ROC analysis, HERC4 positive expression was detected in 1/16
(6.3%) of normal breast tissue, in 3/13 (23.1%) of fibroadenoma, in 6/15 (40%) of intraductal carcinoma and 66/120
(55%) of invasive ductal carcinoma. Positive expression of HERC4 was positively correlated with pT status, pN status,
clinical stage and histological grade of patients with invasive ductal carcinoma (p < 0.05).
Conclusions: Our findings suggest that HERC4 was a significant diagnostic marker for invasive ductal carcinoma
of the breast.
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Breast cancer has been the leading cause in cancers that
threat global women life and health [1]. Breast cancer
has the characteristics of high incidence and mortality
rates. About 1.3 millions women will be diagnosed with
breast cancer and 0.45 millions deaths are estimated
in 2013 according to GLOBOCAN. Different types of
treatment are performed for patients with breast cancer
due to heterogeneity [2,3]. Surgical resection is effective
therapy for early or local cancer, however, this method
may be not suitable when cancer metastasis occurred
[4]. Radiation therapy, chemotherapy, hormone therapy
improve the survival time to some extent, but accompany-
ing pain, resistance and side effects can not be ignored
[5,6]. Breast cancer targeted therapy is a more accurate and* Correspondence: jueyuzhou80@126.com; mawenli668@126.com
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stated.specific treatment that uses certain drugs or other sub-
stances to identify and target cancer cells without harming
normal breast cells. In clinically, estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth
factor type 2 receptor (HER2) are established biomarkers
for breast cancer diagnosis, cancer subtypes analysis
and specific treatment guidance. Furthermore, targeted
therapeutics for breast cancer are mainly concentrated on
HER2 which is tested as overexpression in 20%- 25% of
invasive breast cancers [7]. Trastuzumab and lapatinib are
used as the anti-HER2 first-line drugs for HER2-positive
patients [8]. On the one hand, The overexpression of
HER2 is closely related to poor prognosis and disease-free
interval [9]. On the other hand, targeted therapeutics
against HER2 are more appropriate treatments for meta-
static breast cancer patients with HER2-postive and efficacy
will be discounted for triple-negative breast cancer [8].
Combined with drug resistance, these results promotetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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and targeted therapies.
The mechanisms of molecular tumorigenesis and de-
velopment of breast cancer remain unknown. In general,
breast cancer is closely associated with disorder of gene
expression, gene mutation and destruction of protein
homeostasis [10]. Ubiquitin-proteasome system (UPS)
plays a crucial role in the dynamic balance of intracel-
lular proteins which is different from non-selective
protein degradation by lysosome [11]. Ubiquitin is a
ubiquitous and conserved protein composed of 76 amino
acid. Ubiquitin-proteasome pathway begins with the at-
tachment of ubiquitin to selected protein [12]. The se-
quential biochemical reactions involve three ubiquitin-
related enzymes: ubiquitin activating enzyme (E1 en-
zyme), ubiquitin conjugating enzyme (E2 enzyme) and
ubiquitin ligase (E3 ligase). At last, proteins tagged with
ubiquitin are transported into the 26S proteasome for
specific degradation. Moreover, among the ubiquitin-
related enzymes family, ubiquitin activating enzyme is
unique and the number of ubiquitin conjugating enzyme
is restricted. However, there are numerous ubiquitin li-
gases which determine the specificity of substrate recog-
nition [13]. The normal operation of this mechanism
ensure various life activities, such as cell cycle, apoptosis,
DNA damage response, signal transduction, et. al. If abnor-
mality happens, it would lead to the occurrence of dis-
eases, including cancer [14]. Growing evidences suggest
that ubiquitin-proteasome system holds an important
status in etiology of cancer [15,16]. Consequently, ever-
increasing studies focus on ubiquitin ligases which spe-
cifically recognize substrate protein.
HERC4 is a member of HERC family which is character-
ized by HECT domain and at least one RCC1 (regulator of
chromosome condensation 1)-like domains (RLD). HERC
protein has a dual function that RLD perform the function
of guanine nucleotide exchange factor (GEF) for Ran like
RCC1 and HECT plays a role of ubiquitin ligase [16,17].
HECT domains have about 50% similarity to carboxyl-
terminal region of E6-associated protein (E6AP) which
possesses ubiquitin ligase activity for p53 [18]. Karin et al.,
identified HERC4 firstly and defined HERC4 as the
common ancestor of HERC family by phylogenetic tree
analysis [19]. Immunofluorescence showed HERC4 localize
to the endosome and lysosomes [20]. Murine HERC4 play
a key role in spermatogenesis mediated by loss of proteins
and organelles via ubiquitin-proteasome pathway. Inacti-
vation of murine HERC4 would influence spermatozoon
maturation and consequently results in decrease in male
fertility [21]. However, in human cancer biology, the
physiological substrates and biological functions of
HERC4 are unknown. Therefore, our aim in this study
was to investigate whether HERC4 play a role in the
development of breast cancer and clinical significance.Here we report that HERC4 was up-regulated in tumor
cells of clinical breast cancer samples. The expression
of HERC4 in invasive ductal carcinoma was positively
related to the clinical stage, histological grade and pT
status. Moreover, HERC4 was increasingly expressed in
patients with lymph node metastasis.
Results
Protein expression of HERC4 in breast cancer cell lines
To determine whether expression difference of HERC4
exist between non-tumorigenic cell line and tumorigenic
cell lines, we analysed HERC4 expression in one non-
tumorigenic breast epithelial cell line (MCF-10A) and
five tumorigenic breast epithelial cell line (MCF-7, MDA-
MB-231, T-47D, SK-BR-3 and BT-474) by western blot
(Figure 1). Interestingly, low expression of HERC4 in
MCF-10A and high expression in other tumorigenic cell
lines except for BT-474 were found. This suggested that
breast cancer cells may have a higher expression level of
HERC4.
Protein expression of HERC4 in 32 breast cancer tissues
compared to adjacent nontumor breast tissues
Real-time PCR and western blot analysis were used to
detect HERC4 expression in 32 paired breast cancer and
adjacent normal breast tissues. Similarly, high expression
of HERC4 was founded in clinical breast cancer tissue in
comparison with adjacent normal breast tissues. The
western blot result of four paired samples was showed in
Figure 2A and the value of optical density of the tumorous
(T) and nontumorous (N) tissues was graphically expressed
in Figure 2B. The mRNA expression detected by quantita-
tive real-time PCR was showed in Figure 2C. The result
showed that expression level of HERC4 mRNA was about
6-folds elevated in breast cancer tissues compared with
adjacent normal breast tissues.
Cut-off score selection and immunohistochemical
expression of HERC4 in tissue microarray
IHC was conducted to investigate the expression pattern
of HERC4 in breast cancer and normal breast tissues.
Immunoreactivity was observed primarily in cytoplasm
of tumor cells and IHC staining for HERC4 in represen-
tative samples of breast tumor and normal breast tissues
were shown in Figure 3. Optimal cut-off score for HERC4
was derived from ROC analysis (Figure 4). In our present
study, ROC curve analysis for clinical stage showed that
the point on the curve had the shortest distance to the
point (i.e. 0.0,1.0). Thus, we selected the cut-off score
according to clinical stage and defined tumor as HERC4
positive when HERC4 expression percentage was above
60%. On the basis of cut-off score, HERC4 positive expres-
sion was detected in 1/16 (6.3%) of normal breast tissue, in
3/13 (23.1%) of fibroadenoma, in 6/15 (40%) of intraductal
Figure 1 Western blot analysis of HERC4 expression in breast cancer cell lines. β-actin was used as internal control.
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(Table 1, p < 0.05, χ2-test).
Association of HERC4 protein expression with
clinicopathological parameters
The rates of positive expression of HERC4 with respect to
usual clinicopathological parameters were shown in Table 2.
The results demonstrated HERC4 was expressed increas-
ingly in patients with advanced clinical stage (p < 0.001)
and positive lymph node metastasis (p < 0.001). Moreover,
HERC4 expression was positively correlate with pT status
and histological grade (p < 0.001). There was no significant
difference between HERC4 expression and other features,Figure 2 Real-time PCR and western blot analysis of HERC4 expressio
(A) Western blot indicated significant up-regulation in breast cancer tissues
breast tissues (N1, N2, N3,N4). β-actin was used as internal control. (B) Wester
Significant differences of HERC4 protein expression between tumor (T) and ad
between the optical densities of HERC4 and β-actin. HERC4 protein expressio
differences of HERC4 mRNA level between tumor (T) and adjacent nontumor
expression was significantly higher in breast cancer tissues (P < 0.05). GAPDHsuch as age (≤50 years vs >50 years) or ER, PR, Her2, p53,
Ki67 status (P > 0.05).
Discussion
To date, etiology of breast cancer are unclear. Although
several key genes are identified to be mutated or deregu-
lated in breast cancer such as HER2, P53, cyclin E, and
BRCA1/2 which are involved in tumorigenesis, progression
and metastasis [22,23], the novel molecular markers are
urgently needed for identifying tumor spread and aiding
risk assessment. Last several years, ubiquitin-proteasome
pathway has been seen as a key process in tumorigenesis
[15]. HERC4 is recently identified as a member of HERCn in 32 paired breast cancer and adjacent normal breast tissues.
(T1, T2, T3, T4) in comparison with in the adjacent nontumorous
n blot was calculated as optical density value and expressed graphically.
jacent nontumorous tissues (N) were analyzed statistically using the ratio
n was significantly higher in breast cancer tissues (P < 0.05). (C) Significant
ous tissues (N) were analyzed statistically by 2-ΔΔct method. HERC4 mRNA
was used as internal control.
Figure 3 The expression of HERC4 in adjacent normal breast tissue and breast cancer tissues by IHC. (A) Negative expression of HERC4
was detected in normal breast tissue (100x). (B) Negative expression of HERC4 was detected in an invasive ductal carcinoma (case 57), in which
less than 30% of tumor cells showed positive staining (100x). (C) Positive expression of HERC4 was showed in an invasive ductal carcinoma (case
89) with 80% staining extensity and moderate intensity (100x). (D) Positive expression of HERC4 was showed in an invasive ductal carcinoma
(case 105) with 95% staining extensity and strong intensity (100x). (E), (F), (G) and (H) demonstrate the higher magnification (400x) from the area
of black box in (A), (B), (C) and (D), respectively.
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HERC4 specifically degrades spermatogenesis-related
proteins by ubiquitin-proteasome pathway. Disfunction
of murine HERC4 would prevent spermatozoon from
maturation and influence male fertility [21]. To the best of
our knowledge, the relationship between human HERC4
expression and tumorgenesis has not been reported so far.
Here we study whether HERC4 expression exsit between
breast cancer and adjacent normal breast tissues and its
clinicopathological significance in patients with invasive
ductal carcinoma.
Breast cancer cell lines are preclinical models that
represent different breast tumor subtypes to some extent
and that studies performed with these cell lines can be
transitted to primary breast tumors. Therefore, we detected
the HERC4 expression in breast cell lines by western blot
analysis. The result showed that HERC4 was up-regulated
in nearly all breast cancer cell lines compared to non-
tumorigenic breast epithelial cell line MCF-10A, suggesting
higher expression of HERC4 exists in tumor cells of clinical
breast cancer samples. To validate our inference, we
checked HERC4 expression in 32 paired breast cancer
(13 intraductal carcinoma and 19 histologically confirmed
invasive ductal carcinoma) and adjacent normal breast
tissue samples by quantitative real-time PCR and westernblot analysis. The results were in line with expectations
that expression of HERC4 is significantly higher in the
breast cancer cells than in the adjacent normal breast cells
whether on mRNA level or on protein level (P < 0.05).
Furthermore, to assess clinicopathological significance
of HERC4, we performed immunohistochemical analysis
on a tissue microarray containing 13 benign fibroadenoma,
15 intraductal carcinoma, 120 histologically confirmed
invasive ductal carcinoma and 16 adjacent normal breast
tissue samples. We introduced a scoring system method
based on percentage of positive staining tumor cells to
assess HERC4 immunoreactivity. In order to avoid arbitrary
cutpoints for IHC evaluation of HERC4, ROC analysis was
applied to select optimal cut-off point for HERC4 positivity.
Various ROC curves were plotted according to clinicopath-
ological parameters, including pT stage, pN stage, clinical
stage, histological grade and ER, PR, Her2, p53, Ki67 status.
Finally, the cut-off score was selected to be above 60% for
HERC4 positive expression. On the basis of cut-off point,
positive expression is in 1/16 (6.3%) of normal breast tissue,
in 3/13 (23.1%) of fibroadenoma, in 6/15 (40%) of intra-
ductal carcinoma and 66/120 (55%) of invasive ductal
carcinoma (p < 0.05). Positive expression of HERC4 was
positively correlated with invasive ductal carcinoma pT
status, pN status, clinical stage and histological grade
Figure 4 Receiver operating characteristic (ROC) were applied to select cut-off score for positive expression of HERC4. Various ROC
curves were plotted by sensitivity and specificity for each outcome: (A) histological grade, (B) clinical stage, (C) pT stage, (D) pN stage,
(E) ER status, (F) PR status, (G) Her2 status, (H) p53 status, (I) Ki67 status.
Zhou et al. Cancer Cell International 2013, 13:113 Page 5 of 8
http://www.cancerci.com/content/13/1/113(p < 0.05). These results suggest upregulation of HERC4
in breast cancer promote invasion and/or metastasis of
cancer cells.
Taken together, our result indicated that HERC4 could
be used as a significant diagnostic marker for invasive
ductal carcinoma. As for the mechanisms of HERC4
potential regulation of breast cancer cells invasion and
migration need further investigation.Conclusions
HERC4 is up-regulated in breast cancer cell lines and
breast tumor tissues. Positive expression of HERC4 is
positively correlated with pT status, pN status, clinical
stage and histological grade of patients with invasive ductal
carcinoma of breast (p < 0.05), which suggest that HERC4
may be a potential oncogene of breast cancer and a signifi-
cant diagnostic marker for invasive ductal carcinoma.
Table 1 The expression of HERC4 in normal breast tissues





Normal breast 16 15(93.7) 1(6.3)
Fibroadenoma 13 10(76.9) 3(23.1)
Intraductal carcinoma 15 9(60) 6(40)
Invasive ductal carcinoma 120 54(45) 66(55)
*Values are n (%). A significant increasing frequency of positive expression of
HERC4 was detected in fibroadenoma, intraductal carcinoma, and invasive ductal
carcinoma compared to adjacent normal breast tissue (P = 0.001, χ2-test).
Table 2 Association of HERC4 expression with patient’s
clinicopathological features in 120 invasive ductal
carcinoma
Variables HERC4 staining
Negative(%) Positive(%) Total P valueb
Age(years)
≤50a 25(45.5) 30(54.5) 55 0.927
>50 29(44.6) 36(55.4) 65
pT status
T1 15(88.2) 2(11.8) 17 0.000
T2 36(42.9) 48(57.1) 84
T3 3(18.8) 16(81.2) 19
Lymph node metastasis
Negative 32(80) 8(20) 40 0.000
Positive 22(27.5) 58(72.5) 80
Histology grade
I 41(95.3) 2(4.7) 43 0.000
II 13(24.5) 40(75.5) 53
III 0(0) 24(100) 24
Stage
I-II 43(76.8) 13(23.2) 56 0.000
III-IV 11(17.2) 53(82.8) 64
ER status
Negative 25(43.1) 33(56.9) 58 0.686
Positive 29(46.8) 33(53.2) 62
PR status
Negative 31(50) 31(50) 62 0.255
Positive 23(39.7) 35(60.3) 58
HER2 status
Negative 15(42.9) 20(57.1) 35 0.762
Positive 39(45.9) 46(54.1) 85
P53 status
Negative 23(41.8) 32(58.2) 55 0.519
Positive 31(47.7) 34(52.3) 65
Ki67 status
Negative 15(38.5) 24(61.5) 39 0.318
Positive 39(48.1) 42(51.9) 81
a Mean age.
b P value are from χ2-test.
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Cell lines and cultures
Human non-tumorigenic breast epithelial cell line MCF-
10A, human breast cancer cell lines MCF-7, MDA-MB-
231, T-47D, SK-BR-3 and BT-474 were obtained from
laboratory preservation. MCF-10A was grown in Dulbecco’s
modified Eagle’s medium/F12 medium (15 mM hepes
buffer, Hyclone, U.S.A.) containing 5% (vol/vol) donor
equine serum, 10 μg/ml insulin, 20 ng/ml epidermal growth
factor, 500 ng/ml hydrocortisone, 100 ng/ml cholera toxin,
100 units/mL penicillin and 100 μg/mL streptomycin
(Hyclone, U.S.A.). Five human breast cancer cell lines were
cultured in Dulbecco’s modified Eagle’s medium (DMEM
High Glucose, Hyclone, U.S.A.) supplemented with 10%
(vol/vol) fetal bovine serum (Gibco, U.S.A.), 100 units/mL
penicillin and 100 μg/mL streptomycin (Hyclone, U.S.A.).
All cell lines were cultured at 37°C in a 5% CO2-humidified
atmosphere.
Patients and tissue samples
In this study, a total of 148 paraffin-embedded tissue
samples from patients with breast tumors who received no
prior treatments were enrolled for immunohistochemistry.
Moreover, another 32 fresh paired breast cancer (13 intra-
ductal carcinoma and 19 histologically confirmed invasive
ductal carcinoma) and adjacent normal breast tissue
samples were collected for quantitative real-time PCR and
western blot analysis. All the samples were collected from
Nanfang Hospital and Zhujiang Hospital of Southern
Medical University between 2005 and 2012. The paraffin-
embedded tumor cases included 13 benign fibroadenoma,
15 intraductal carcinoma and 120 histologically confirmed
invasive ductal carcinoma. In addition, 16 adjacent normal
tissue samples were added as control group. Clinicopatho-
logic information of patients included age at diagnosis, pT
status, lymph node metastasis, clinical stage, histology
grade and IHC results of Her-2, ER, PR, p53, and Ki67.
Ages of the 120 patients with invasive ductal carcinoma
ranged from 26 to 71 years (mean, 50 years) and detailed
data were shown in Table 2. The histologic grade was
assessed according to Bloom–Richardson classification.This study was performed under a protocol approved by
the Ethic Committee of the Nanfang Hospital with written
informed consent of all patients for research.
RNA isolation, reverse transcription and real-time PCR
Quantitative real-time PCR was adopted to relatively
quantify and assess the mRNA expression of HERC4 in
clinical samples. Total RNAs were isolated from fresh
breast tissues using RNAiso Plus (Takara, China) and
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tion and purity were measured by Biophotometer plus
(Eppendorf, Germany). Besides, RNA samples were ana-
lysed for following procedures only when OD A260/A280
ratio was between 1.8 and 2.0. First-strand cDNAs were
synthesized from qualified mRNAs by using PrimeScript®
RT reagent Kit (Takara, China) according to product
manual. Quantitative real-time PCR were performed by
using the SYBR® Premix Ex TaqTM II Kit (Takara, China)
in an ABI 7500 real-time PCR amplifier (Applied Biosys-
tems, U.S.A.). The primer sequences were listed in Table 3.
The PCR conditions were as follows: 95°C for 30 s, 40 cycles
of amplification at 95°C for 5 s and 60°C for 34 s, followed
by additional dissociation stage for testing reaction specifi-
city. Each PCR reaction was repeated 3 times for stable re-
sults. Expression of HERC4 was normalized with respect
to GADPH and fold changes were analyzed using the
Comparative Ct (ΔΔct) method.
Western blot
Total proteins were extracted from cell lines and breast
tissue samples using Radio-Immunoprecipitation Assay
(RIPA) buffer containing 1 mM PMSF (Beyotime, China).
Then protein concentration was determined by BCA
Protein Assay Kit (Beyotime, China) and adjusted to a
final concentration of 5 μg/ μL using the RIPA buffer.
The protein samples were mixed with the loading buffer
(Beyotime, China) in a volume ratio of 4 to 1 and were
boiled for 5 min for denaturalization. Finally, 10 μL mix-
ture of each sample was loaded for 10% SDS-PAGE gel
electrophoresis and then transferred on a polyvinylidene
fluoride (PVDF) membrane by a Semi-Dry transfer ma-
chine (Trans-blot SD, BioRad, USA). The membrane was
blocked by 5% nonfat milk dissolved in Tris-Buffered Saline
and Tween 20(1 X TBST) solution at room temperature
for 2 h. Afterwards the membrane was immediately
separately incubated with HERC4 primary antibody
(Rabbit polyclonal, 1:1000, PL laboratories, U.S.A.) and β-
actin primary antibody (Mouse monoclonal, 1:2000, Neo-
Bioscience, China) at 4°C overnight. The membrane was
washed by 1X TBST for 3 times and then incubated
with corresponding HRP conjugated-secondary anti-
bodies (Goat anti-Rabbit IgG, 1:5000, EarthOx, U.S.A.;
Goat anti-Mouse IgG, 1:5000, NeoBioscience, China)
at room temperature for 1 h, followed by 1 X TBSTTable 3 Primers used in real-time PCR





GAPDH: Glyceraldehyde-3-phosphate dehydrogenase, as internal control.washing 3 times. Eventually, immunoreactive bands
were visualized by using the BeyoECL Plus Kit
(Beyotime, China) and figures were scanned by the
Image Station 4000R PRO instrument (CareStream
Health, U.S.A.). Protein bands were quantified as optical
density value using Gel-Pro analyzer (Media Cybernetics,
U.S.A.) and β-actin was set as internal control.
Tissue microarrays (TMA) construction and
immunohistochemistry
Tissue microarray was constructed according to standard
method. Briefly, duplicate 0.6 mm diameter cylinders were
punched from representative areas of tumor or normal tis-
sue blocks (donor tissue block). Next, cylinders were re-
embeded into a new paraffin block (recipient paraffin block)
at predefined positions using a tissue-arraying instrument
(Minicore, Mitogen, U.K.). Finally, 5-μm sections were cut
from TMA block for immuohistochemistry analysis.
Immunohistochemical staining was carried out according
to standard procedures. Formalin-fixed and paraffin-em-
bedded tissue array was immersed in xylene for deparaffi-
nization and in graded ethanol for rehydration. Before
antigen retrieval treated with sodium citrate buffer (pH
6.0) at 100°C for 20 min, activities of endogenous hydro-
gen peroxidase were inhibited by 0.3% H2O2. Subse-
quently, tissue array was incubated with 5% normal goat
serum for blocking, followed by incubation with HERC4
primary antibody (Rabbit polyclonal, 1:200, PL laborator-
ies, U.S.A.) at 4°C overnight. After 3 times of washing by
1X PBS, tissue array was incubated at room temperature
for 30 min with polymer peroxidase-labeled secondary
antibody (Zhongshan biotech, China). Finally, counter-
staining was performed by hematoxylin. Signal was vis-
ualized by using DAB Horseradish Peroxidase Color
Development Kit (Beyotime, China). Phosphate-buffered
saline replaced anti-HERC4 antibody as a negative control.
IHC evaluation
Immunohistochemical expression of HERC4 was scored
by three authors independently using a semi-quantitative
scoring method. It was based on the evluation of percent-
age of positive tumor cells over the total tumor cells. The
scores were expressed as 5% increments (0, 5%, 10%…
100%). When difference appeared among the three authors,
results were re-estimated until a consensus was reached.
Selection of cut-off score
Receiver operating characteristic (ROC) curve analysis
was introduced to reach an optimal cutoff score for tumor
with increased HERC4 expression using 0,1-criterion. For
ROC analysis, the clinicopathological parameters were
dichotomized as follows: pT stage (T1-T2, T3-T4), pN
stage (N0, N1), clinical stage (I-II, III-IV), histological grade
(G1-G2, G3) and ER, PR, Her2, p53, Ki67 status (negative,
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paired sensitivity and specificity of different HERC4
scores. The score closest to the point [0.0, 1.0] on the
curve (i.e. the point with both maximum sensitivity
and specificity) was treated as the cut-off score. Thus,
tumors were defined “negative” when HERC4 score below
the threshold. On the contrary, when HERC4 score was
above the threshold, tumors was defined “positive”.
Statistical analysis
All statistical analyses was performed with SPSS 13.0
software (SPSS, Chicago, IL, USA). Measurement data were
showed as the mean ± SD. T test were used to assess
expression differences within groups. Receiver operating
characteristic (ROC) was applied to reach optimal cut-off
score for HERC4 positive. The association between HERC4
expression and the clinicopathological parameters of the
breast cancer patients was estimated with Chi-square test.
Differences were considered significant when the P-value
was <0.05 (two-tailed test).
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